Want to see JP:4593 full AI Analyst Report?
Top Page
Healios KK
(4593)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥297.00
▼(-19.73% Downside)
Action:Reiterated
Date:08/21/26
The score is held down primarily by weak financial performance—sharp operating losses, negative gross margin, and heavy ongoing cash burn—despite improved leverage. Technicals are only moderately supportive (positive MACD and above short-term averages) but the longer-term trend remains challenged, and valuation is demanding with a high P/E and no dividend yield provided.
Positive Factors
Regenerative medicine platform
Healios is focused on regenerative medicine, somatic stem cells, and iPSC-derived cells across multiple therapeutic areas. This platform orientation can support several clinical and commercial opportunities over time, while manufacturing capabilities may strengthen its ability to advance cell-based therapies.
Negative Factors
Declining revenue
The decline and volatility in revenue indicate that Healios has not yet established a stable commercial earnings base. Unpredictable top-line performance can make it harder to fund research, negotiate partnerships from strength, and demonstrate durable operating progress over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Regenerative medicine platform
Healios is focused on regenerative medicine, somatic stem cells, and iPSC-derived cells across multiple therapeutic areas. This platform orientation can support several clinical and commercial opportunities over time, while manufacturing capabilities may strengthen its ability to advance cell-based therapies.
Read all positive factors
Healios KK (4593) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥40.93B
Dividend YieldN/A
Average Volume (3M)1.62M
Price to Earnings (P/E)59.5
Beta (1Y)1.10
Revenue Growth-47.32%
EPS GrowthN/A
CountryJP
Employees75
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)4.96
Shares Outstanding135,545,600
10 Day Avg. Volume1,684,710
30 Day Avg. Volume1,617,123
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-35.05
Revenue Forecast (FY)¥595.02M
Healios KK Business Overview & Revenue Model
Company Description
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets in...
How the Company Makes Money
Healios makes money primarily through (1) revenue from collaboration and licensing arrangements (including upfront payments, milestone payments tied to development/regulatory progress, and potential royalties on partnered products if commercialize...
Healios KK Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.00M | 104.00M | 560.00M | 121.00M | 90.00M | 41.00M |
| Gross Profit | -341.00M | -389.00M | 432.00M | 108.00M | 90.00M | 41.00M |
| EBITDA | -2.58B | -3.13B | -2.54B | -3.16B | -4.52B | -3.61B |
| Net Income | 206.00M | -2.22B | -4.24B | -3.82B | -5.17B | -4.91B |
Balance Sheet | ||||||
| Total Assets | 23.12B | 17.05B | 14.19B | 15.15B | 15.03B | 23.97B |
| Cash, Cash Equivalents and Short-Term Investments | 9.07B | 5.68B | 3.67B | 6.72B | 7.25B | 15.13B |
| Total Debt | 2.57B | 2.61B | 2.66B | 4.53B | 7.15B | 11.96B |
| Total Liabilities | 14.31B | 12.15B | 12.11B | 11.29B | 10.65B | 15.33B |
| Stockholders Equity | 8.77B | 4.89B | 2.06B | 3.86B | 4.38B | 8.64B |
Cash Flow | ||||||
| Free Cash Flow | -4.38B | -3.33B | -1.83B | -2.85B | -4.86B | -5.39B |
| Operating Cash Flow | -4.10B | -3.17B | -1.82B | -2.82B | -4.60B | -5.09B |
| Investing Cash Flow | -1.64B | -1.11B | -1.42B | -1.12B | -909.00M | -736.00M |
| Financing Cash Flow | 8.51B | 6.33B | 77.00M | 3.34B | -2.50B | 6.99B |
Healios KK Technical Analysis
Positive
370.00
Price Trends
276.54
Positive
276.54
Positive
317.90
Negative
Market Momentum
6.08
Negative
55.03
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4593, the sentiment is Positive. The current price of 370 is above the 20-day moving average (MA) of 292.60, above the 50-day MA of 276.54, and above the 200-day MA of 317.90, indicating a neutral trend. The MACD of 6.08 indicates Negative momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4593.
Healios KK Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ¥40.93B | 59.48 | ― | ― | -47.32% | ― | |
46 Neutral | ¥32.20B | -72.14 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥13.51B | -28.32 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥8.34B | -7.18 | ― | ― | -56.16% | 3.12% | |
43 Neutral | ¥79.54B | -20.69 | -37.79% | ― | ― | 5.71% | |
40 Underperform | ¥10.28B | -5.39 | ― | ― | ― | 4.68% |
* General Sector Average
JP:4593
Healios KK
302.00
-166.00
-35.47%
JP:4592
SanBio Co
1,019.00
-2,831.00
-73.53%
JP:4599
StemRIM Inc.
164.00
-125.00
-43.25%
JP:4978
ReproCELL Inc.
130.00
-45.00
-25.71%
JP:7774
Japan Tissue Engineering Co., Ltd.
793.00
307.00
63.17%
JP:7776
CellSeed Inc.
211.00
-255.00
-54.72%
Healios KK Corporate Events
Healios books first culture supernatant revenue with JENECELL cosmetics deal
Oct 5, 2026
Healios K.K. has completed its first commercial shipment of somatic stem cell culture supernatant products, worth about ¥144 million, to South Korea-based JENECELL for use as a raw material in cosmetics, and has recognized the related revenue...
Healios Delays Initial Stem Cell Supernatant Shipment to JENECELL
Sep 30, 2026
Healios K.K., a Japanese regenerative medicine biotech, is advancing somatic stem cell culture supernatant products alongside its clinical-stage stem cell therapies. The company has agreed to supply human bone marrow-derived somatic stem cell cult...
Healios Flags Disclosure Limits in FY2026 Q2 Results Material
Aug 12, 2026
Healios K.K., a player in regenerative medicine, focuses on developing and commercializing advanced cell-based therapies and medical technologies for markets with significant unmet clinical needs. The company emphasizes careful handling of economi...
Healios Secures AMED Funding to Industrialize iPSC-Derived NK Cell Therapy
Jul 27, 2026
Healios K.K., a clinical-stage regenerative medicine biotech in Japan, is developing stem cell-based therapies including its flagship MAPC-derived product HLCM051 for inflammatory and ischemic conditions, and iPSC-derived enhanced natural killer c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.